Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Apr

Today In Oncology

Comparative Effectiveness of Acupuncture vs Massage for Relieving Pain in Patients With Advanced Cancer

Risk of Second Primary Breast Cancer in Young Breast Cancer Survivors

Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

Improving Early Detection of Pancreatic Cancer in High-Risk Patients

Survival Rates in Patients With Cancer and Intellectual and Developmental Disabilities

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Related Videos

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Amit Sanyal, MD: A Clinician’s Perspective